Psyence Biomedical
9 hedge funds and large institutions have $1.24M invested in Psyence Biomedical in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 0 closing their positions.
350% more funds holding
Funds holding: 2 → 9 (+7)
116% more capital invested
Capital invested by funds: $575K → $1.24M (+$665K)
40.86% less ownership
Funds ownership: 50.53% → 9.66% (-41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$555K |
| 2 |
Morgan Stanley
New York
|
+$172K |
| 3 |
Jane Street
New York
|
+$138K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$68.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$53.1K |
Top Sellers
PBM Hedge Fund Activity: Q2 2026 in Review
9 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q2 2026, worth a combined $1.24M — up 116% from $575K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PBM positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $555K.
- 9 institutional investors held Psyence Biomedical (PBM) as of Q2 2026, up from 2 in Q1 2026.
- Funds reported $1.24M of Psyence Biomedical stock for Q2 2026, up 116% quarter-over-quarter.
- 7 funds opened new Psyence Biomedical positions in Q2 2026 and 0 closed out, a net change of +7 holders.
- The largest Psyence Biomedical buyer in Q2 2026 was AdvisorShares Investments, an estimated $555K added.
Based on aggregated 13F filings for Q2 2026.